Regulatory-grade clinical trial design using real-world data
- PMID: 32063037
- PMCID: PMC8697198
- DOI: 10.1177/1740774520905576
Regulatory-grade clinical trial design using real-world data
Abstract
Real-world data and evidence provide the potential to address the effectiveness and safety of drugs. The U.S. Food & Drug Administration has initiated a program to evaluate the potential use of real-world evidence for regulatory uses. Whether a study is designed for regulatory purposes or for other purposes, existing regulation and guidance provide a reference for high-quality studies. Clarifying the study objectives and the role of real-world data in the study are important considerations. Robustness and transparency of the analysis allow for greater understanding and acceptance of the study results.
Keywords: Evidence; bias; heterogeneity; real-world.
References
-
- United States Food and Drug Administration. Guidance for Industry and FDA Staff: Best practices for conducting and reporting pharmacoepidemiologic safety studies using electronic healthcare data sets, https://www.fda.gov/regulatory-information/search-fda-guidance-documents... (2013, accessed 13 September 2019).
-
- Platt R, Wilson M, Chan KA, et al. The new Sentinel Network-improving the evidence of medical-product safety. N Engl J Med 2009; 361: 645–647. - PubMed
-
- Platt R, Brown JS, Robb M, et al. The FDA Sentinel Initiative - An evolving national resource. N Engl J Med 2018; 379: 2091–2093. - PubMed
-
- Cocoros NM, Pokorney SD, Haynes K, et al. FDA-Catalyst-Using FDA’s Sentinel Initiative for large-scale pragmatic randomized trials: approach and lessons learned during the planning phase of the first trial. Clin Trials 2019; 16: 90–97. - PubMed
-
- United States Food and Drug Administration. Framework for FDA’s real-world evidence program, https://www.fda.gov/media/120060/download (2018, accessed 13 September 2019).
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
